Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10512620 | ALTATHERA PHARMS LLC | Method of initiating and escalating sotalol hydrochloride dosing |
Aug, 2038
(14 years from now) | |
US11696902 | ALTATHERA PHARMS LLC | Method of initiating and escalating sotalol hydrochloride dosing |
Aug, 2038
(14 years from now) | |
US10799138 | ALTATHERA PHARMS LLC | Method of administering sotalol IV/switch |
Apr, 2039
(15 years from now) | |
US11583216 | ALTATHERA PHARMS LLC | Method of administering sotalol IV/switch |
Aug, 2039
(15 years from now) |
Sotalol Hydrochloride is owned by Altathera Pharms Llc.
Sotalol Hydrochloride contains Sotalol Hydrochloride.
Sotalol Hydrochloride has a total of 4 drug patents out of which 0 drug patents have expired.
Sotalol Hydrochloride was authorised for market use on 02 July, 2009.
Sotalol Hydrochloride is available in solution;intravenous dosage forms.
Sotalol Hydrochloride can be used as use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia, dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation., intravenous sotalol dosing regimen for use in a facility that can provide electrocardiographic monitoring.
The generics of Sotalol Hydrochloride are possible to be released after 21 August, 2039.
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.; Use for loading dose in patients with sy...
Dosage: SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic